Analysts’ Weekly Ratings Updates for Centessa Pharmaceuticals (CNTA)

Centessa Pharmaceuticals (NASDAQ: CNTA) has recently received a number of price target changes and ratings updates:

• 4/2/2026 – Centessa Pharmaceuticals was downgraded by Guggenheim from “buy” to “hold”.
• 4/1/2026 – Centessa Pharmaceuticals was downgraded by Lifesci Capital from “strong-buy” to “hold”.
• 4/1/2026 – Centessa Pharmaceuticals was downgraded by Leerink Partners from “outperform” to “hold”. They now have a $40.00 price target on the stock, up from $36.00.
• 3/31/2026 – Centessa Pharmaceuticals was downgraded by B. Riley Financial, Inc. from “strong-buy” to “hold”.
• 3/31/2026 – Centessa Pharmaceuticals was downgraded by Stephens from “strong-buy” to “hold”.
• 3/31/2026 – Centessa Pharmaceuticals was downgraded by Wolfe Research from “outperform” to “hold”.
• 3/31/2026 – Centessa Pharmaceuticals was downgraded by Needham & Company LLC from “buy” to “hold”.
• 2/24/2026 – Centessa Pharmaceuticals is now covered by Wolfe Research. They set an “outperform” rating and a $40.00 price target on the stock.
• 2/23/2026 – Centessa Pharmaceuticals was upgraded by Wolfe Research to “strong-buy”.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 73,196 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the completion of the transaction, the insider owned 65,925 shares of the company’s stock, valued at $1,735,805.25. This represents a 52.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Iqbal J. Hussain sold 38,951 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the transaction, the insider directly owned 57,645 shares of the company’s stock, valued at approximately $1,449,771.75. This trade represents a 40.32% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 349,073 shares of company stock worth $9,429,412. 7.09% of the stock is owned by company insiders.

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.